AdipoGen Life Sciences

Ac-Trp-Leu-Ala-AMC

CHF 70.00
In stock
AG-CP3-0035-M0011 mgCHF 70.00
AG-CP3-0035-M0055 mgCHF 280.00
More Information
Product Details
Synonyms Ac-WLA-AMC; Proteasome Substrate
Product Type Chemical
Properties
Formula

C32H37N5O6

MW 587.7
Sequence

Acetyl-Trp-Leu-Ala-7-amido-4-methylcoumarin

CAS 1104011-59-7
Purity Chemicals ≥98% (HPLC)
Appearance Lyophilized powder.
Solubility Soluble in DMSO.
Identity Determined by MS
Other Product Data

Use: After preparing a stock solution in DMSO (≥10mM) store product at -20°C to -80°C. It is recommended to make multiple aliquots after the first thaw to ensure best performance. Chymotrypsin-like activity can be measured using a typical working concentration range from 10-50µM.

InChi Key PIJMRHCPKXLMIS-DOYMOWJKSA-N
Smiles CC(C1=CC=C(C=C1O2)NC([C@H](C)NC([C@H](CC(C)C)NC([C@@H](NC(C)=O)CC3=CNC4=CC=CC=C34)=O)=O)=O)=CC2=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Protect from light.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Fluorogenic peptide substrate for measuring chymotrypsin-like activity of the 20S proteasome. This substrate is hydrolyzed by the β5-subunit of the 20S proteasome to generate detectable fluorescence. 20S Proteasome enzyme requires activation with 0.035% SDS in the assay buffer.
  • Excitation: 345nm. Emission: 445nm.
  • Specific substrate to the constitutive proteasome, not hydrolyzed efficiently by the immunoproteasome.
  • This substrate is useful for inhibitor screening and kinetic analysis.
Product References
  1. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit: C. Blackburn, et al.; Biochem. J. 430, 461 (2010)
  2. The immunoproteasome as a therapeutic target for hematological malignancies: Z. Miller, et al.; Curr. Can. Drug Targets 14, 537 (2014)
  3. Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases: R. Ettari, et al.; Curr. Med. Chem. 23, 1217 (2016)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.